Abstract:(rociohv@ucm.es) Glaucoma is a leading cause of blindness worldwide. In this neurodegenerative disease, a progressive death of retinal ganglion cells (RGC) and a glaucomatous optic disc neuropathy occurs which lead to visual impairment. Increase of Intraocular pressure (IOP) is a major risk factor strongly associated with retinal degeneration although a non IOP‐dependent neurodegeneration also occurs. Neurodegeneration process observed in glaucoma and other chronic retinal diseases occurs through different pathways: glutamate‐induced RGC cytotoxicity, apoptosis, neurotrophic factors deprivation, oxidative stress, calcium channel alteration and inflammation, among others. Due to the multifactorial character of the disease there is special interest in designing treatments able to include a combination of active agents in the same formulation. Unlike treatment to control IOP, which acts on the anterior segment of the eye and it can be administered topically, the applicability of neuroprotective therapies requires the administration of the active substances near to the retinal tissues using intraocular injections. Furthermore, due to the chronicity of the disease frequents administrations are required to reach and maintain therapeutic concentrations in the target site. Intraocular drug delivery systems are able to provide effective concentrations inside the eye for long term, thus reducing the number of interventions. Among the controlled release devices, implants (>1 mm) and microparticles (1–1000 μm), are capable of releasing the active substance in the vicinity of the retina for extended periods of time. Furthermore, if they are prepared with biodegradable polymers as the case of poly‐(lactic‐co‐glycolic) (PLGA), they have the advantage of disappearing from the site of administration after releasing the drug. Moreover, the final products of these biodegradable biomaterials result well tolerated and are finally eliminated from the body. Among the intraocular drug delivery devices, microspheres present a lot of advantages as they can be administered as a suspension in the vitreous using small gauge needles (30‐32G) without the need to surgery or stitches, which is more comfortable for ophthalmologists and patients, also reducing the risk of infection. Microspheres can be loaded with different agents that can be delivered simultaneously during long term. Another interesting advantage of microspheres is that, by being able to easily modify the amount of microparticles to be administered, they become very useful tools for personalized therapies. Thus, with these microsystems the number of administrations could be considerably reduced, spacing them even several months. Bravo‐Osuna I., Andrés‐Guerrero V., Arranz‐Romera A., Esteban‐Pérez S., Molina‐Martínez I.T., Herrero‐Vanrell R. Microspheres as intraocular therapeutic tools in chronic diseases of the optic nerve and retina. (2018) Advanced drug delivery reviews 126, 127–144. Acknowledgments: Grants PID2020‐113281RB‐C21 and PID2020‐113281RB‐C22 funded by MCIN/AEI/ 10.13039/501100011033 ; N° 813440 (ORBITAL– Ocular Research by Integrated Training and Learning).

A new paradigm for treatment of glaucoma

Promising Approach in the Treatment of Glaucoma Using Nanotechnology and Nanomedicine-Based Systems

Nanomedicines for the Treatment of Glaucoma: Current Status and Future Perspectives

Near-Infrared Activated Liposomes for Neuroprotection in Glaucoma

Technological Advances in a Therapy of Primary Open-Angle Glaucoma: Insights into Current Nanotechnologies

Intraocular nano-microscale drug delivery systems for glaucoma treatment: design strategies and recent progress

Nanotechnology for Medical and Surgical Glaucoma Therapy—A Review

Review: Neuroprotective Nanocarriers in Glaucoma

Nanomedicine in glaucoma treatment; Current challenges and future perspectives

Multifunctional nano-in-micro delivery systems for targeted therapy in fundus neovascularization diseases

Glaucoma: Biological Trabecular and Neuroretinal Pathology with Perspectives of Therapy Innovation and Preventive Diagnosis

Gene therapy strategies for glaucoma from IOP reduction to retinal neuroprotection: progress towards non-viral systems

Multiloaded drug delivery devices for the treatment of glaucoma

Point-of-Care Nanoplatforms for Glaucoma and Age-Related Macular Degeneration: Clinical Implications and Emerging Concepts

Unveiling enigmatic essence of Sphingolipids: A promising avenue for glaucoma treatment

Newer advances in medical management of glaucoma

Advances in Neuroprotection in Glaucoma: Pharmacological Strategies and Emerging Technologies

Innovative Nanotechnology in Drug Delivery Systems for Advanced Treatment of Posterior Segment Ocular Diseases

Therapeutic strategies for glaucoma and optic neuropathies

Nanomedicine and drug delivery to the retina: current status and implications for gene therapy

Current Medical Therapy and Future Trends in the Management of Glaucoma Treatment